Skip to main content
All lobbying filings

Rare Disease Company Coalition

Rare Disease Company Coalition filed a Q2 report for Rare Disease Company Coalition on July 16, 2026.

Lobbying for Rare Disease Company Coalition · Healthcare

As filed: RARE DISEASE COMPANY COALITION for RARE DISEASE COMPANY COALITION.

All filings by Rare Disease Company Coalition · Everything Rare Disease Company Coalition has reported

 Filing · LD-2 quarterly report Q2 report
Reporting period
2nd Quarter 2026
Apr 1 - June 30 · Posted Jul 16, 2026
Expenses
$70,000
What this organization spent lobbying with its own staff. Reported using the LDA's own definitions (method A): the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.
Client based in
District of Columbia

Official filing document

 Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

 Lobbying activity 1
Pharmacy

HR 1 / Public Law - ORPHAN Cures Act HR 1414 - Camerons Law HR 7148 / Public Law 119-75 - PRV Reauthorization CMS-5545-P - Global Benchmark for Efficient Drug Pricing (GLOBE) CMS-5546-P - Guarding U.S. Medicare Against Rising Drug Costs (GUARD) Proclamation 11020 - Exemption for Orphan Drugs from 232 Pharmaceutical Tariffs Rare Disease Innovation Issues

 Bills named in this filing 3

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem